Android app on Google Play

Goldman Sachs Starts Regeneron Pharma (REGN) at Buy, Sees 23% Upside

April 2, 2012 6:45 AM EDT Send to a Friend
Get Alerts REGN Hot Sheet
Price: $363.06 +3.60%

Rating Summary:
    16 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 13 | New: 52
Trade REGN Now!
Join SI Premium – FREE
Goldman Sachs initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy and $144 price target, suggesting 23% upside. The firm said Eylea is on its way to blockbuster status.

"The key driver for shares is recently launched drug, Eylea, for a variety of eye diseases that lead to vision loss," the analyst said. "We anticipate continued robust uptake of Eylea (GS WW peak sales of $4bn, $2.3bn in US), which we project will propel the company to sustainable profitability in 4Q12."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $116.62 yesterday.




You May Also Be Interested In


Related Categories

Hot New Coverage, New Coverage

Related Entities

Goldman Sachs

Add Your Comment